SCC-31

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameSCC-31
Drug Alias NameSCC-31LXI-15029MTI-31
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsSolid tumoursBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShandong Luoxin Pharmaceutical Group Stock Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of SciencesFudan University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFudan UniversityShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShandong Luoxin Pharmaceutical Group Stock Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A